Skip to content

4579.T

RaQualia Pharma Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 550.00
+0.92%
Ask drillr

Year over year

Reported trailing growth

Revenue
+28.1%
EBITDA
+4739.9%
EBIT
+326.8%
EPS
+147.7%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
-2.3%
EBITDA
EPS

Three-year CAGR

Revenue
+10.9%
EBITDA
-12.2%
EBIT
-17.7%
Net income
-27.7%
EPS
-30.6%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026